Abstract
Mucopolysaccharosis III (MPS III) is a lysosomal storage disorder and belongs to the group of mucopolysaccharidoses. MPS III is caused by a deficiency of one of the four enzymes catalyzing the degradation of the glycosaminoglycan heparan sulfate. MPS III is clinically characterized by progressive dementia with distinct behavioral disturbances and relatively mild somatic disease. This review will summarize and discuss the available and potential future therapeutic options for patients with MPS III. This includes enzyme replacement therapy (ERT), hematopoietic stem cell transplantation (HSCT), substrate reduction therapy (SRT), chaperone-mediated therapy, and gene therapy. Although clinical efficacy has not yet been fully demonstrated for any of these therapies, it is likely that future developments will lead to disease- modifying treatment for this devastating disease.
Keywords: Enzyme replacement therapy, gene therapy, hematopoietic stem cell transplantation, mucopolysaccharidosis iii, sanfilippo syndrome, substrate reduction therapy, lysosomal storage disorder, glycosaminoglycan heparan sulfate, behavioral disturbances, hematopoietic stem cell transplantation (HSCT), chaperone-mediated therapy, disease-modifying treatmen, autosomal recessive inherited deficiency
Current Pharmaceutical Biotechnology
Title: Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Emerging Treatment Strategies
Volume: 12 Issue: 6
Author(s): J. de Ruijter, M. J. Valstar and F. A. Wijburg
Affiliation:
Keywords: Enzyme replacement therapy, gene therapy, hematopoietic stem cell transplantation, mucopolysaccharidosis iii, sanfilippo syndrome, substrate reduction therapy, lysosomal storage disorder, glycosaminoglycan heparan sulfate, behavioral disturbances, hematopoietic stem cell transplantation (HSCT), chaperone-mediated therapy, disease-modifying treatmen, autosomal recessive inherited deficiency
Abstract: Mucopolysaccharosis III (MPS III) is a lysosomal storage disorder and belongs to the group of mucopolysaccharidoses. MPS III is caused by a deficiency of one of the four enzymes catalyzing the degradation of the glycosaminoglycan heparan sulfate. MPS III is clinically characterized by progressive dementia with distinct behavioral disturbances and relatively mild somatic disease. This review will summarize and discuss the available and potential future therapeutic options for patients with MPS III. This includes enzyme replacement therapy (ERT), hematopoietic stem cell transplantation (HSCT), substrate reduction therapy (SRT), chaperone-mediated therapy, and gene therapy. Although clinical efficacy has not yet been fully demonstrated for any of these therapies, it is likely that future developments will lead to disease- modifying treatment for this devastating disease.
Export Options
About this article
Cite this article as:
de Ruijter J., J. Valstar M. and A. Wijburg F., Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Emerging Treatment Strategies, Current Pharmaceutical Biotechnology 2011; 12 (6) . https://dx.doi.org/10.2174/138920111795542651
DOI https://dx.doi.org/10.2174/138920111795542651 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Breaking the Barrier in Stroke: What Should we Know? A Mini-Review
Current Pharmaceutical Design Candidate Susceptibility Genes in Alzheimers Disease Are at High Risk for Being Forgotten - They Dont Give Peace of Mind...
Current Drug Metabolism Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders
Current Protein & Peptide Science Bioactivity of Chitosan and Its Derivatives
Current Organic Chemistry The Physiological Characteristics and Transcytosis Mechanisms of the Blood-Brain Barrier (BBB)
Current Pharmaceutical Biotechnology From Stem Cells to Dopamine Neurons: Developmental Biology Meets Neurodegeneration
CNS & Neurological Disorders - Drug Targets Regression to the Mean: Implications for Clinical Trials of Psychotropic Agents in Dementia
Current Alzheimer Research Potential for Treatment of Neurodegenerative Diseases with Natural Products or Synthetic Compounds that Stabilize Microtubules
Current Pharmaceutical Design APP/PS1 Gene-Environment Noise Interaction Aggravates AD-like Neuropathology in Hippocampus <i>Via</i> Activation of the VDAC1 Positive Feedback Loop
Current Alzheimer Research Butyrylcholinesterase as a Diagnostic and Therapeutic Target for Alzheimer’s Disease
Current Alzheimer Research Neuroprotective Effects of Estrogens: Cross-Talk Between Estrogen and Intracellular Insulin Signalling
Infectious Disorders - Drug Targets Inflammation in Ischemic Stroke: Mechanisms, Consequences and Possible Drug Targets
CNS & Neurological Disorders - Drug Targets Anti-α4β1 Integrin Antibodies Attenuated Brain Inflammatory Changes in a Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Passive Smoking, Endothelial Dysfunction and Related Markers in Healthy Individuals: An Update
Current Hypertension Reviews Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication
Current Alzheimer Research Adenosine Neuromodulation and Traumatic Brain Injury
Current Neuropharmacology Targeting PPARalpha in Alzheimer's Disease
Current Alzheimer Research Pharmacological Management of Acutely Agitated Schizophrenic Patients
Current Pharmaceutical Design Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Current Topics in Medicinal Chemistry Recent Advances in Nanoneurology for Drug Delivery to the Brain
Current Nanoscience